ABCG2 and non-small cell lung carcinoma: However, drug resistance can be developed in patients with NSCLC treated with topotecan, which may be related to ABCG2 overexpression as topotecan is a substrate transported by ABCG2 (Mo and Zhang, 2012; Zhang et al., 2018).